Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer

Song Yao, William E. Barlow, Kathy S. Albain, Ji Yeob Choi, Hua Zhao, Robert B Livingston, Warren Davis, James M. Rae, I. Tien Yeh, Laura F. Hutchins, Peter M. Ravdin, Silvana Martino, Alan P. Lyss, C. Kent Osborne, Martin D. Abeloff, Gabriel N. Hortobagyi, Daniel F. Hayes, Christine B. Ambrosone

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

To date, the few studies of associations between a functional polymorphism in the oxidative stress-related gene manganese superoxide dismutase (SOD2) and breast cancer survival have been inconsistent. In a homogeneous patient population from a large cooperative group trial Southwest Oncology Group (SWOG) 8897, we evaluated this polymorphism in relation to both treatment-related toxicity and disease-free survival (DFS). Among 458 women who received cyclophosphamide-containing adjuvant chemotherapy, those with variant C alleles, related to higher antioxidant activity, experienced less grade 3-4 neutropenia (OR = 0.52, 95% CI = 0.29-0.92) but had worse DFS (HR = 1.59, 95% CI = 0.99-2.55) than women with TT genotypes. No associations were observed among 874 women who were followed without adjuvant therapy. Our results are consistent with the hypothesis that women with higher SOD2 antioxidant activity may experience less treatment-related toxicity but shorter time to disease recurrence or death after breast cancer adjuvant chemotherapy, supporting the modifying effects of oxidative stress-related enzymes on cancer treatment toxicity and efficacy.

Original languageEnglish (US)
Pages (from-to)433-439
Number of pages7
JournalBreast Cancer Research and Treatment
Volume124
Issue number2
DOIs
StatePublished - Nov 2010

Fingerprint

Disease-Free Survival
Superoxide Dismutase
Clinical Trials
Breast Neoplasms
Adjuvant Chemotherapy
Oxidative Stress
Antioxidants
Therapeutics
Neutropenia
Cyclophosphamide
Alleles
Genotype
Recurrence
Survival
Enzymes
Population
Genes
Neoplasms

Keywords

  • Disease-free survival
  • Polymorphism
  • SNP
  • SOD2
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. / Yao, Song; Barlow, William E.; Albain, Kathy S.; Choi, Ji Yeob; Zhao, Hua; Livingston, Robert B; Davis, Warren; Rae, James M.; Yeh, I. Tien; Hutchins, Laura F.; Ravdin, Peter M.; Martino, Silvana; Lyss, Alan P.; Kent Osborne, C.; Abeloff, Martin D.; Hortobagyi, Gabriel N.; Hayes, Daniel F.; Ambrosone, Christine B.

In: Breast Cancer Research and Treatment, Vol. 124, No. 2, 11.2010, p. 433-439.

Research output: Contribution to journalArticle

Yao, S, Barlow, WE, Albain, KS, Choi, JY, Zhao, H, Livingston, RB, Davis, W, Rae, JM, Yeh, IT, Hutchins, LF, Ravdin, PM, Martino, S, Lyss, AP, Kent Osborne, C, Abeloff, MD, Hortobagyi, GN, Hayes, DF & Ambrosone, CB 2010, 'Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer', Breast Cancer Research and Treatment, vol. 124, no. 2, pp. 433-439. https://doi.org/10.1007/s10549-010-0840-0
Yao, Song ; Barlow, William E. ; Albain, Kathy S. ; Choi, Ji Yeob ; Zhao, Hua ; Livingston, Robert B ; Davis, Warren ; Rae, James M. ; Yeh, I. Tien ; Hutchins, Laura F. ; Ravdin, Peter M. ; Martino, Silvana ; Lyss, Alan P. ; Kent Osborne, C. ; Abeloff, Martin D. ; Hortobagyi, Gabriel N. ; Hayes, Daniel F. ; Ambrosone, Christine B. / Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. In: Breast Cancer Research and Treatment. 2010 ; Vol. 124, No. 2. pp. 433-439.
@article{4c0c0a7ff60947078f0b4cb993a8dd23,
title = "Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer",
abstract = "To date, the few studies of associations between a functional polymorphism in the oxidative stress-related gene manganese superoxide dismutase (SOD2) and breast cancer survival have been inconsistent. In a homogeneous patient population from a large cooperative group trial Southwest Oncology Group (SWOG) 8897, we evaluated this polymorphism in relation to both treatment-related toxicity and disease-free survival (DFS). Among 458 women who received cyclophosphamide-containing adjuvant chemotherapy, those with variant C alleles, related to higher antioxidant activity, experienced less grade 3-4 neutropenia (OR = 0.52, 95{\%} CI = 0.29-0.92) but had worse DFS (HR = 1.59, 95{\%} CI = 0.99-2.55) than women with TT genotypes. No associations were observed among 874 women who were followed without adjuvant therapy. Our results are consistent with the hypothesis that women with higher SOD2 antioxidant activity may experience less treatment-related toxicity but shorter time to disease recurrence or death after breast cancer adjuvant chemotherapy, supporting the modifying effects of oxidative stress-related enzymes on cancer treatment toxicity and efficacy.",
keywords = "Disease-free survival, Polymorphism, SNP, SOD2, Toxicity",
author = "Song Yao and Barlow, {William E.} and Albain, {Kathy S.} and Choi, {Ji Yeob} and Hua Zhao and Livingston, {Robert B} and Warren Davis and Rae, {James M.} and Yeh, {I. Tien} and Hutchins, {Laura F.} and Ravdin, {Peter M.} and Silvana Martino and Lyss, {Alan P.} and {Kent Osborne}, C. and Abeloff, {Martin D.} and Hortobagyi, {Gabriel N.} and Hayes, {Daniel F.} and Ambrosone, {Christine B.}",
year = "2010",
month = "11",
doi = "10.1007/s10549-010-0840-0",
language = "English (US)",
volume = "124",
pages = "433--439",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer

AU - Yao, Song

AU - Barlow, William E.

AU - Albain, Kathy S.

AU - Choi, Ji Yeob

AU - Zhao, Hua

AU - Livingston, Robert B

AU - Davis, Warren

AU - Rae, James M.

AU - Yeh, I. Tien

AU - Hutchins, Laura F.

AU - Ravdin, Peter M.

AU - Martino, Silvana

AU - Lyss, Alan P.

AU - Kent Osborne, C.

AU - Abeloff, Martin D.

AU - Hortobagyi, Gabriel N.

AU - Hayes, Daniel F.

AU - Ambrosone, Christine B.

PY - 2010/11

Y1 - 2010/11

N2 - To date, the few studies of associations between a functional polymorphism in the oxidative stress-related gene manganese superoxide dismutase (SOD2) and breast cancer survival have been inconsistent. In a homogeneous patient population from a large cooperative group trial Southwest Oncology Group (SWOG) 8897, we evaluated this polymorphism in relation to both treatment-related toxicity and disease-free survival (DFS). Among 458 women who received cyclophosphamide-containing adjuvant chemotherapy, those with variant C alleles, related to higher antioxidant activity, experienced less grade 3-4 neutropenia (OR = 0.52, 95% CI = 0.29-0.92) but had worse DFS (HR = 1.59, 95% CI = 0.99-2.55) than women with TT genotypes. No associations were observed among 874 women who were followed without adjuvant therapy. Our results are consistent with the hypothesis that women with higher SOD2 antioxidant activity may experience less treatment-related toxicity but shorter time to disease recurrence or death after breast cancer adjuvant chemotherapy, supporting the modifying effects of oxidative stress-related enzymes on cancer treatment toxicity and efficacy.

AB - To date, the few studies of associations between a functional polymorphism in the oxidative stress-related gene manganese superoxide dismutase (SOD2) and breast cancer survival have been inconsistent. In a homogeneous patient population from a large cooperative group trial Southwest Oncology Group (SWOG) 8897, we evaluated this polymorphism in relation to both treatment-related toxicity and disease-free survival (DFS). Among 458 women who received cyclophosphamide-containing adjuvant chemotherapy, those with variant C alleles, related to higher antioxidant activity, experienced less grade 3-4 neutropenia (OR = 0.52, 95% CI = 0.29-0.92) but had worse DFS (HR = 1.59, 95% CI = 0.99-2.55) than women with TT genotypes. No associations were observed among 874 women who were followed without adjuvant therapy. Our results are consistent with the hypothesis that women with higher SOD2 antioxidant activity may experience less treatment-related toxicity but shorter time to disease recurrence or death after breast cancer adjuvant chemotherapy, supporting the modifying effects of oxidative stress-related enzymes on cancer treatment toxicity and efficacy.

KW - Disease-free survival

KW - Polymorphism

KW - SNP

KW - SOD2

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=78649325635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649325635&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-0840-0

DO - 10.1007/s10549-010-0840-0

M3 - Article

C2 - 20309628

AN - SCOPUS:78649325635

VL - 124

SP - 433

EP - 439

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -